A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

Utah

Utah

Global health R&D delivers for Utah

US government investment in global health R&D has delivered

Amount
$93.1 million
to Utah research institutions
Jobs
1,500+ new jobs
for Utah
Utah's top USG-funded global health R&D institutions

Utah's top USG-funded global health R&D institutions

University of Utah
$51.1 million
Utah State University
$19.4 million
BioFire Diagnostics Inc.
$10.8 million
Navigen Inc.*
$10.1 million
Brigham Young University
$960 thousand
Gradient Biomodeling, LLC
$278 thousand
NanoSynth Materials and Sensors*
$278 thousand
Carterra Inc. (formerly Wasatch Microfluidics)
$136 thousand

Utah's top areas of global health R&D by USG funding

3%
Arenaviral hemorrhagic fevers (including Lassa fever)
2.2%
Bunyaviral diseases (including CCHF, RVF, SFTS)
6.6%
COVID-19
10.5%
Diarrheal diseases
2.2%
Emergent non-polio enteroviruses (including EV71, D68)
6%
Flioviral diseases (including Ebola, Marburg)
16.1%
HIV/AIDS
8.9%
Malaria
11.5%
Neglected tropical diseases
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
3.8%
Reproductive health
6.9%
Salmonella infections
2.2%
Zika
20%
Other
Bacterial pneumonia & meningitis
Chikungunya
Cryptococcal meningitis
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Tuberculosis
Utah

Neglected and emerging diseases in Utah

Chikungunya cases
Chikungunya cases
3
Dengue cases
Dengue cases
13
HIV diagnoses
HIV diagnoses
354
Malaria cases
Malaria cases
80
Malaria cases
Mpox cases
6
Tuberculosis cases
Tuberculosis cases
181
Global health R&D at work in Utah

Researchers at Utah State University supported preclinical testing of a broad-spectrum antiviral drug that has shown potential to treat a variety of dangerous pathogens, including Marburg, Ebola, yellow fever, and Zika viruses. The research was supported by the National Institute of Allergy and Infectious Diseases within the US National Institutes of Health as part of its programming to advance solutions for emerging infectious disease threats. While approved treatments are now available for Ebola Zaire, there are no specific treatments approved for Marburg, yellow fever, Zika, or Ebola Sudan—underscoring the importance of continued antiviral drug development.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIAID/NIH